Global Markets for Vaccine Technologies

NEW YORK, Jan. 26, 2017 /PRNewswire/ --

Use this report to:
- Identify the areas of market growth among vaccine manufacturers and users.
- Gain insight into the regulatory aspects, current and developing technologies, market projections and market share with respect to vaccine technologies.
- Receive information on the acquisition strategies and collaborations by companies along with the strengths and weaknesses of each strategy type.
- Evaluate the market size for human and animal vaccines.

Highlights
- The global market for vaccine technologies reached $33.3 billion in 2016 and should reach $45.2 billion by 2021, growing at a compound annual growth rate (CAGR) of 6.3% from 2016 to 2021.
- Human vaccines as a segment of this market reached $27.2 billion in 2016 and should reach nearly $37.5 billion by 2021, growing at a CAGR of 6.6% from 2016 to 2021.
- Animal vaccines as a segment of this market reached nearly $6.1 billion in 2016 and should reach $7.7 billion by 2021, growing at a CAGR of 4.9% from 2016 to 2021.

STUDY OBJECTIVES
Vaccines are an important part of the global healthcare market. Human vaccines are available for a wide range of diseases such as polio; measles, mumps and rubella (MMR); tetanus; diphtheria; hepatitis and influenza. Animal health vaccines offer applications such as antibiotics, parasiticides and medicinal feed additives and vaccines for both livestock and companion animals. BCC Research's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for vaccine technology.

This report explores present and future strategies within the vaccine technology market, which is divided into vaccines for both humans and animals. The outlook of the market, the setbacks and the needs of the market are discussed in this report. The classifications and usage of these products are also described in this report.

A detailed analysis of the vaccine technology industry's structure has been conducted. The revenues are broken down by region, while sales figures are estimated for the five-year period from 2016 through 2021. The applications of these vaccines are discussed separately in the report. The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THIS STUDY
Vaccines are one of the most cost-effective ways to reduce the global disease load. The global rise in infectious and noninfectious diseases, the growing population, advancements in science and technology, as well as the resurgence of vaccine preventable diseases and the emergence of new pandemics and immunization programs run in developing geographies are influencing the global vaccines market.

In humans, vaccines are used to prevent or treat various human diseases. Based on whether they prevent diseases or treat pre-existing ones, vaccines can be divided broadly into prophylactic and therapeutic vaccines. In contrast, animal vaccines are categorized for food-producing animals (porcine, bovine, poultry, ovine, fish) and for companion animals (canine, feline and equine vaccines) and other animal vaccines (rabbit, etc.).

Research and development (R&D spending, along with increasing competition and new technologies are giving direction to the market. These advancements, new product launches and changing lifestyles are influencing future market growth. This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. In addition, this study also discusses the strengths and weaknesses of each strategy type in light of the new technologies, growing competition and changing customer needs.

The market also has been analyzed based on the application of these vaccines. Categories considered in this report are meningococcal/pneumococcal vaccines, influenza vaccines, pediatric polio/pertussis/Hib vaccines, adult/adolescent booster vaccines, vaccines for travel-related and other endemic diseases, HPV vaccines, rotavirus vaccines and other (minor) vaccines.

CONTRIBUTIONS OF THE STUDY AND FOR WHOM
This study contributes to the areas of market growth among vaccine manufacturers and users. Genomic research centers, academic institutions, government and private laboratories, various hospital settings as well as pharmaceutical, diagnostic and biotechnology companies and physicians will find this study to be of interest.

SCOPE OF THE STUDY
The scope of this study entails the current market for human and animal vaccines. The report also includes regulatory aspects, current and developing technologies, market projections and market share. An analysis of patents, clinical trials, innovations and opportunities, as well as the latest trends is also discussed. Sales data for the global and regional markets were corroborated for the present and forecasted values based on statistical analysis. Regions are categorized into the United States, Europe and the emerging markets, which include India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand. The application of vaccines in various diseases is discussed from both a commercial and R&D perspective.

METHODOLOGY
Both primary and secondary research methodologies were used in preparing this study. BCC Research conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with manufacturers and users of vaccine technology products. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

INFORMATION SOURCES
Many companies were surveyed to obtain data for this study. Included were manufacturers and end users of vaccine technology. Data were gathered from various industry sources. In addition, BCC Research interviewed industry officials, consulted newsletters, company literature, product literature and various technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

ANALYSTS' CREDENTIALS
The study has been carried out by a team of professionals in the biotechnology industry. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has more than 17 years of industry experience. She was awarded a Gold Medal by the prime minister of India for her work and has worked with top companies in India and in the United States.

Read the full report: http://www.reportlinker.com/p01595226-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com


__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-markets-for-vaccine-technologies-300397764.html

SOURCE Reportlinker